Notably, Alox5 overexpression significantly delayed the progression of MLL-AF9 AML in secondary BMT recipients (median overall survival, 42.5 days (MA9_Alox5) vs. 37 days (MA9_Ctrl); P = 0.018, log-rank test) (Fig. 2d). The gene discussed is KMT2A; the disease is acute myeloid leukemia.